Abstract
The preparation of certain 2-(2-oxo-2
-chromen-4-yl)-
-substituted acetamides
was planned as a step in the development of new modified nonsteroidal antiestrogens. The purity of target compounds
was checked by thin-layer chromatography (TLC), and their structures were confirmed using various spectroscopic tools including IR,
H-NMR,
C-NMR, and MS spectroscopy. Viability tests were applied using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay to evaluate the cytotoxic effect of the synthesized compounds against two breast cancer cell lines, MCF-7 and MDA-MB-231. Compound
proved the most active against MCF-7 cells, with an IC
value of 0.32 μM. The results of an analysis of in vitro antiestrogenic activity indicated that only compound
exhibited antiestrogenic activity; its IC
value of 29.49 μM was about twice as potent as that of the reference compound, MIBP. The aromatase activity was evaluated for the synthesized target compounds
and the intermediates
and
. A significant aromatase inhibition was observed for the intermediate
and compound
, with IC
values of 14.5 and 17.4 μM, respectively. Compound
, namely 7-methoxy-4-(2-oxo-2-(piperidin-1-yl)ethyl)-2H-chromen-2-one, could be used as an antiestrogen and/or cytotoxic agent with selective activity against tumor cells.